N/A N=22 Transcranial Magnetic Stimulation for BECTS
Benign Epilepsy With Centrotemporal Spikes · Language Problems · Learning Disorders
Primary: Interictal Epileptiform Discharge (IED) Frequency — 0; 0; 0; 0 IEDs per 5 minutes — p=0.04
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=5 Treating Deep Seizure Foci With Noninvasive Surface Brain Stimulation
Epilepsy, Temporal Lobe
Primary: Self-reported Seizure Frequency — 6.4 seizure days per 4 weeks
Phase 4 N=8 Perampanel in Seizure Patients With Primary Glial Brain Tumors
Brain Tumor, Primary
Primary: Percentage of Patients With ≥50% Seizure Reduction During the Maintenance Period Compared With Seizure Frequency Before Initiation of Perampanel
N/A N=93 Study of Lacosamide as an Adjunctive Drug Treatment for Epilepsy in Patients With Brain Tumors
Brain Tumor Related Epilepsy (BTRE)
Primary: Percentage of Patients With Response at the End of the 6-month Observation Period — 76.7 percentage of patients
N/A N=58 Functional Monitoring for Motor Pathway in Brain Tumor Surgery Within Eloquent Area
Glioma, Motor Pathway
Primary: Extent of Tumor Resection — 40; 7; 7; 4 participants
N/A N=11 Treatment of Difficult to Control Focal Epilepsy With Repetitive Transcranial Magnetic Stimulation (rTMS)
Epilepsies, Partial
Primary: 50% Responder Rate After Active rTMS Treatment Compared With Placebo Treatment — 0; 0; 0; 0 participants
Phase 2 N=12 Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Glioma, Malignant · Surgery · Seizures
Primary: Peritumoral HFO Rate — 2.5; 1.4 HFOs per minute
Phase 2 N=126 Levetiracetam to Prevent Post-Traumatic Epilepsy
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
Phase 2 N=15 A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD
Epilepsy · Tuberous Sclerosis Complex · Focal Cortical Dysplasia
Primary: Number of Patients With Adverse Events — 0; 0 Participants
Phase 1 N=21 Characterization of Epilepsy Patients BEEP 2b
Epilepsy
Primary: Mean AUC0-last_ss (Test vs. Reference) — 92.884; 62.76666667; 419.97; 260.3 micro/mL/hr
Phase 2 N=20 Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC)
Epilepsy · Tuberous Sclerosis Complex
Primary: Reduction in Seizure Frequency — 60 percentage
N/A N=60 Neocortical Epilepsies - Do They Progress?
Epilepsy
Primary: Functional Connectivity
N/A N=10 Treating Non-epileptic Seizures Using Magnetic Brain Stimulation
Nonepileptic Seizures
Primary: Number of Weekly Psychogenic Non-epileptic Seizure-events — 6.9; 5.3 events
Phase 2 N=30 Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Glioblastoma · Gliosarcoma
Primary: Feasibility as Assessed by Successful Co-registration of sMRI-based Treatment Volumes With Clinical Images Into the Radiation Treatment Execution Platform — 30…
N/A N=167 Stereotactic Laser Ablation for Temporal Lobe Epilepsy (Slate)
Temporal Lobe Epilepsy
Primary: Incidence of Qualifying Adverse Events — 7.9 percentage of participants
N/A N=11 Image-Guided Stereotactic Biopsy of High Grade Gliomas
Brain Cancer · Glioma
Primary: Invest Relation Btw Voxel-based Determ of Prolif Rate & Obser MR Imaging Featu (i.e., Ktrans or Microvas Permeabil; fBV, Tiss Fract Blood Vol), as Well With Spatially…
Phase 2 N=84 Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Phase 2 N=66 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
Glioblastoma Multiforme · Gliosarcoma
Primary: Overall Survival — 19 months
Phase 2 N=50 External Trigeminal Nerve Stimulation for Epilepsy
Epilepsy · Seizure Disorders
Primary: 50% Responder Rate — 40.5; 15.6 percentage of participants
Early Phase 1 N=6 Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
Blood Brain Barrier Defect
Primary: Change in AUC0-18 of the Temozolomide Concentration (AUC-T) in Brain Interstitium Before and After Regadenoson Infusion — 19.1; 18.0 percentage of AUC
N/A N=12 rTMS and Botulinum Toxin in Benign Essential Blepharospasm
Benign Essential Blepharospasm
Primary: Change in JRS Severity Score — -1.8; -0.1 Change in score
Phase 4 N=81 1 Week Versus 6 Weeks of Levetiracetam in Surgical Brain Tumor Patients
Brain Neoplasms · Brain Cancer · Brain Tumors
Primary: Change in Neurotoxicity Scale Scores — -1; -3.5 score on scale — p=0.7824
Phase 3 N=109 SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy
Epilepsy
Primary: Primary Analysis: Change in Seizure Rate — -40.4; -14.5 Percentage change from baseline — p=0.0017
N/A N=13 Bevacizumab w / Temozolomide PET & Vascular MRI For GBM
Recurrent Glioblastoma
Primary: Number of Patients With a Decrease in Median Tumor SUV — 6 Participants
Phase 2 N=43 Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Phase 2 N=43 Valproic Acid With Temozolomide and Radiation Therapy to Treat Brain Tumors
High Grade Gliomas · Brain Tumors
Primary: Median Progression Free Survival. — 10.5 months
Phase 2 N=7 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
Astrocytoma, Grades II, III and IV · Glioblastoma Multiforme · Giant Cell Glioblastoma
Primary: Number of Participants With the Presence of Drug in the Tumor Tissue — 2 Participants
Phase 2 N=66 BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations
IDH1 Mutation · IDH2 Mutation · Recurrent Glioblastoma
Primary: Participants With Dose Limiting Toxicity (DLT) Rate Less Than or Equal to 33% (Dose Level 1) — 0; 7 Participants
N/A N=17 Arterial Spin Labeling MRI Focal Abnormalities in Refractory Epilepsy
Focal Epilepsy
Primary: Intensity of the MRI Signal in the Left Temporal Precentral Zone — 1.06; 1.04 ratio
N/A N=17 High Frequency Oscillation in Pediatric Epilepsy Surgery
Pediatric Epilepsy · Epilepsy Surgery · High Frequency Oscillation
Primary: Post-operative Seizure-free Rate — 4; 5; 4; 4 Participants